Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL).
Boutsikas G, Terpos E, Markopoulos A, Papatheodorou A, Stefanou A, Georgiou G, Galani Z, Komninaka V, Telonis V, Anagnostopoulos I, Dimitrakopoulou L, Anargyrou K, Tsionos K, Christoulas D, Gonianaki M, Giannikos T, Kokoris S, Konstantopoulos K, Meletis J, Angelopoulou MK, Travlou A, Vassilakopoulos TP. Boutsikas G, et al. Among authors: anargyrou k. J BUON. 2017 Jul-Aug;22(4):1022-1031. J BUON. 2017. PMID: 28952223 Free article.
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.
Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, Dimopoulos MA, Terpos E. Anargyrou K, et al. Hemasphere. 2019 Sep 24;3(6):e303. doi: 10.1097/HS9.0000000000000303. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976477 Free PMC article.
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P. Angelopoulou MK, et al. Among authors: anargyrou k. Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002/hon.2383. Epub 2017 Feb 20. Hematol Oncol. 2018. PMID: 28219112 Free PMC article.
Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.
Tsirkinidis P, Terpos E, Boutsikas G, Papatheodorou A, Anargyrou K, Lalou E, Dimitrakopoulou A, Kalpadakis C, Konstantopoulos K, Siakantaris M, Panayiotidis P, Pangalis G, Kyrtsonis MC, Vassilakopoulos T, Angelopoulou MK. Tsirkinidis P, et al. Among authors: anargyrou k. J Bone Miner Metab. 2018 Jul;36(4):399-409. doi: 10.1007/s00774-017-0853-4. Epub 2017 Jun 28. J Bone Miner Metab. 2018. PMID: 28660376
Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy.
Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Boutsis DE, Anargyrou K, Kokoris SI, Giannakakis A, Karkantaris C, Kyrtsonis MC, Tsaftaridis P, Rombos J, Variamis E, Korkolopoulou P, Kittas C, Pangalis GA. Vassilakopoulos TP, et al. Among authors: anargyrou k. Eur J Haematol. 2002 May;68(5):289-98. doi: 10.1034/j.1600-0609.2002.01721.x. Eur J Haematol. 2002. PMID: 12144535
Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA. Vassilakopoulos TP, et al. Among authors: anargyrou k. Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):765-81. doi: 10.1016/j.ijrobp.2003.11.029. Int J Radiat Oncol Biol Phys. 2004. PMID: 15183480
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC; Greek Myeloma Study Group. Anargyrou K, et al. Haematologica. 2008 Mar;93(3):451-4. doi: 10.3324/haematol.11852. Epub 2008 Feb 20. Haematologica. 2008. PMID: 18287135 Free article.
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece. Terpos E, et al. Among authors: anargyrou k. Int J Cancer. 2012 Feb 1;130(3):735-42. doi: 10.1002/ijc.26062. Epub 2011 May 30. Int J Cancer. 2012. PMID: 21484787
39 results